Cargando…

Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors

Background: Most patients with advanced gastrointestinal stromal tumors (GIST) develop drug resistance to tyrosine kinase inhibitors (TKIs) within two years of starting therapy, whereas most chronic myeloid leukemia (CML) patients in chronic phase still exhibit disease control after a decade on ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomasetti, Cristian, Demetri, George D, Parmigiani, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000Research 2013
Materias:	Short Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892920/ https://www.ncbi.nlm.nih.gov/pubmed/24555070 http://dx.doi.org/10.12688/f1000research.2-152.v1

Ejemplares similares

Downsizing Treatment with Tyrosine Kinase Inhibitors in Patients with Advanced Gastrointestinal Stromal Tumors Improved Resectability
por: Sjölund, Katarina, et al.
Publicado: (2010)

Advanced gastrointestinal stromal tumor patients benefit from palliative surgery after tyrosine kinase inhibitors therapy
por: Qiu, Hai-Bo, et al.
Publicado: (2018)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors
por: Li, Jian, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review
por: Feng, Mingyang, et al.
Publicado: (2022)

Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors
por: Na, Young-Soon, et al.
Publicado: (2017)

The Role of Surgical Resection Following Tyrosine Kinase Inhibitors Treatment in Patients with Advanced Gastrointestinal Stromal Tumors: A Systematic Review and Meta-analysis
por: Guo, Yinghao, et al.
Publicado: (2019)

Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
por: Bauer, Sebastian, et al.
Publicado: (2021)

Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors
por: Pantaleo, Maria A, et al.
Publicado: (2014)

A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance
por: Boichuk, Sergei, et al.
Publicado: (2017)

Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors
por: Obata, Y, et al.
Publicado: (2017)

Prognostic value of Onodera’s nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors
por: Wang, Feng, et al.
Publicado: (2021)

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)
por: Mahadevan, Daruka, et al.
Publicado: (2014)

Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal Tumor
por: Venkataraman, Vinayak, et al.
Publicado: (2023)

Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors
por: Sardinha, Ruth, et al.
Publicado: (2013)

Neoadjuvant tyrosine kinase inhibitors in rectal gastrointestinal stromal tumours: a provision for enhanced oncological and functional outcomes
por: Yong, Zachary Zihui, et al.
Publicado: (2021)

Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials
por: Wu, Lile, et al.
Publicado: (2014)

Long-term progression-free survival achieved in the skull base metastasis of gastrointestinal stromal tumor with introduction of tyrosine kinase inhibitor: illustrative case
por: Kawanishi, Akiya, et al.
Publicado: (2022)

Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)

The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why?
por: Kaczmarska, Agnieszka, et al.
Publicado: (2021)

Novel Anthraquinone-based Derivatives as Potent Inhibitors for Receptor Tyrosine Kinases
por: Stasevych, M., et al.
Publicado: (2015)

Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)
por: Le Tourneau, Christophe, et al.
Publicado: (2007)

Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature
por: van de Wal, Deborah, et al.
Publicado: (2022)

Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review
por: Zhang, Yefan, et al.
Publicado: (2023)

Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors
por: Lee, Ji Hyun, et al.
Publicado: (2022)

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations
por: Hu, S, et al.
Publicado: (2014)

Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
por: Halbach, Sebastian, et al.
Publicado: (2016)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
por: Hempel, Cornelius, et al.
Publicado: (2017)

The effect of gastrectomy on regorafenib exposure and progression‐free survival in patients with advanced gastrointestinal stromal tumours
por: Lubberman, Floor J.E., et al.
Publicado: (2019)

Recent advances in the management of gastrointestinal stromal tumors
por: Duffaud, Florence, et al.
Publicado: (2010)

Recent advances in managing gastrointestinal stromal tumor
por: Duffaud, Florence, et al.
Publicado: (2017)

Advances and Challenges on Management of Gastrointestinal Stromal Tumors
por: Mei, Lin, et al.
Publicado: (2018)

New advances in radiomics of gastrointestinal stromal tumors
por: Cannella, Roberto, et al.
Publicado: (2020)

Recent advances in the management of gastrointestinal stromal tumor
por: Ahmed, Monjur
Publicado: (2020)

Ripretinib for the treatment of advanced gastrointestinal stromal tumor
por: Zalcberg, John R.
Publicado: (2021)

Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors
por: Van Looy, Thomas, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer and Eye Metastasis: Disease Relapse or a New Entity?
por: ZAROGOULIDIS, Paul, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nqo2hhb30f7691rpq64752sokb